MedTrace Logo

Blocking Blue Light in Pregnancy, Effects on Melatonin Profile and Sleep

NCT03114072 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-18

No results posted yet for this study

Summary

Sleep disturbances are common in pregnancy, and the incidence increases during the third trimester. Light and specially the blue wavelengths of light, is affecting sleep and the circadian rhythm. The main aim of this randomized controlled study is to investigate the effect of Blue-blocking glasses (BB-glasses) used in the evening and night on sleep and mood in pregnant women in the third trimester. The outcome measures assess sleep variables, alertness, melatonin level, sleepiness (subjectively), mood and symptoms of anxiety and depression. In addition we want to measure the pregnancy related sleep problems, alcohol intake, physical activity and perceives stress in the study population, and the association with daily/nightly light exposure.

Conditions

  • Sleep Disturbance

Interventions

DEVICE

Blue-blocking glasses

Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.

DEVICE

Light grey control glasses

Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.

Sponsors & Collaborators

  • The Norwegian Competence Center for Sleep Disorders (SOVno)

    collaborator UNKNOWN

  • Western Norway University of Applied Sciences

    collaborator OTHER

  • University of Bergen

    lead OTHER

Principal Investigators

  • Randi Liset, PhD · University of Bergen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2019-04-09
Completion
2026-07-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03114072 on ClinicalTrials.gov